Nerandomilast (Jascayd)
Small molecule
Evidence outlook
Approved: Idiopathic Pulmonary Fibrosis
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also in development:Systemic Sclerosis · Phase 3
Also approved (5)
- Progressive pulmonary fibrosis (PPF) in adult patients
- Jascayd is indicated for the treatment of adult patients with Idiopathic Pulmonary Fibrosis (IPF). Jascayd is indicated for the treatment of adult patients with Progressive Pulmonary Fibrosis (PPF).
- Adults with idiopathic pulmonary fibrosis (IPF) and adults with progressive pulmonary fibrosis (PPF)
- Adults with progressive pulmonary fibrosis (PPF)
- Idiopathic pulmonary fibrosis (IPF)
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT05321069 NCT05321069 · Idiopathic Pulmonary Fibrosis This was a large, randomized, quadruple-blind, placebo-controlled trial with 1,177 participants and a hard physiological primary endpoint: change in lung function measured by forced vital capacity. The primary endpoint was statistically significant in favor of nerandomilast for both 9 mg and 18 mg doses versus placebo. Registry: NCT05321069 | 3 | Absolute Change From Baseline in Forced Vital Capacity (FVC) [mL] at Week 52 (The MMRM model is a longitudinal analysis, and it incorporated FVC measurements from baseline (Week -8 to Week -1) and Week 2, Week 6, Week 12, Week 18, Week 26, Week 36, Week 44 and Week 52. The data represent the Least Squares Mean at Week 52) 2024-08-16 | Absolute Change From Baseline in Forced Vital Capacity (FVC) [mL] at Week 52 (The MMRM model is a longitudinal analysis, and it incorporated FVC measurements from baseline (Week -8 to Week -1) and Week 2, Week 6, Week 12, Week 18, Week 26, Week 36, Week 44 and Week 52. The data represent the Least Squares Mean at Week 52): Placebo -183.48 Milliliters (mL) (95% CI -210.86 to -156.1) | Nerandomilast 9 mg BID -138.6 Milliliters (mL) (95% CI -165.59 to -111.61) | Nerandomilast 18 mg BID -114.65 Milliliters (mL) (95% CI -141.81 to -87.5) | Reliable signal | link ↗ |
View 2 more trials
FIBRONEER-ON NCT06238622 · Idiopathic Pulmonary Fibrosis Registry: NCT06238622 | 3 | Occurrence of any adverse event over the course of the extension trial (yes/no) i.e. up until the follow-up/end of study visit planned at the latest at week 99 (Up to 99 weeks and 3 days) 2027-04-28 | In progress: results expected 28 Apr 2027 | not yet graded | link ↗ |
NCT04419506 NCT04419506 · Idiopathic Pulmonary Fibrosis Nerandomilast was compared with a matching placebo in 147 randomly assigned patients, with participants, carers, investigators and assessors all blinded. The primary measure, change in forced vital capacity at 12 weeks, favoured nerandomilast in both patients without background antifibrotics (difference 88.4 mL, 95% credible interval 29.5 to 154.2) and patients taking them (62.4 mL, 6.3 to 125.5). The protocol reports a sample-size calculation based on at least 120 patients, and 147 were enrolled. Registry: NCT04419506 | 2 | The Change From Baseline in Forced Vital Capacity (FVC) at 12 Weeks (Baseline (day 1) and week 12.) 2021-10-06 | The Change From Baseline in Forced Vital Capacity (FVC) at 12 Weeks (Baseline (day 1) and week 12.): Placebo - Antifibrotics at Baseline -77.7 Milliliter (95% CI -124.87 to -30.53) | BI 1015550 - Antifibrotics at Baseline 2.72 Milliliter (95% CI -33.46 to 38.89) | Placebo - Non-antifibrotics at Baseline -95.62 Milliliter (95% CI -157.13 to -34.1) | BI 1015550 - Non-antifibrotics at Baseline 6.1 Milliliter (95% CI -39.67 to 51.88) | Reliable signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (9)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (1)
What this study did
Phase 2 (3)
What this study did
What this study did
What this study did
Phase 1 (23)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (1)
What this study did
Competitive landscape
Other PDE4B drugs
1 other tracked programme targets this mechanism, none of them ahead of this one.
This drug's own stage for Idiopathic Pulmonary Fibrosis: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Nerandomilast (Jascayd): this drug | Approved | Small molecule | PDE4B | Reliable signal | NCT05321069: Absolute Change From Baseline in Forced Vital Capacity (FVC) [mL] at Week 52 (The MMRM model is a longitudinal analysis, and it incorporated FVC measurements from baseline (Week -8 to Week -1) and Week 2, Week 6, Week 12, Week 18, Week 26, Week 36, Week 44 and Week 52. The data represent the Least Squares Mean at Week 52): Placebo -183.48 Milliliters (mL) (95% CI -210.86 to -156.1) | Nerandomilast 9 mg BID -138.6 Milliliters (mL) (95% CI -165.59 to -111.61) | Nerandomilast 18 mg BID -114.65 Milliliters (mL) (95% CI -141.81 to -87.5) NCT04419506: The Change From Baseline in Forced Vital Capacity (FVC) at 12 Weeks (Baseline (day 1) and week 12.): Placebo - Antifibrotics at Baseline -77.7 Milliliter (95% CI -124.87 to -30.53) | BI 1015550 - Antifibrotics at Baseline 2.72 Milliliter (95% CI -33.46 to 38.89) | Placebo - Non-antifibrotics at Baseline -95.62 Milliliter (95% CI -157.13 to -34.1) | BI 1015550 - Non-antifibrotics at Baseline 6.1 Milliliter (95% CI -39.67 to 51.88) | |
| Nintedanib (Ofev) | Approved | Small molecule | Triple angiokinase inhibitor (VEGFR/FGFR/PDGFR) | Partial signal | NCT01335464: INPULSIS-1, annual rate of FVC decline over 52 weeks, nintedanib 150 mg twice daily (n=309) vs placebo (n=204): -114.65 vs -239.91 mL/year; difference 125.26 mL/year (95% CI 77.68 to 172.84), p < 0.0001 (CT.gov posted results). NCT01335477: INPULSIS-2, annual rate of FVC decline over 52 weeks, nintedanib 150 mg twice daily (n=329) vs placebo (n=219): -113.59 vs -207.32 mL/year; difference 93.73 mL/year (95% CI 44.78 to 142.68), p = 0.0002 (CT.gov posted results). | |
| Pirfenidone (Esbriet) | Approved | Small molecule | Pyridone | Reliable signal | NCT01366209: At week 52, decline in percent predicted FVC of 10 points or more, or death: pirfenidone 16.5% vs placebo 31.8% (relative reduction 47.9%); no FVC decline 22.7% vs 9.7%; P<0.001 (ASCEND, NEJM 2014; CT.gov posted results). | |
| Treprostinil (Tyvaso DPI) | Approved(overall) | Small molecule | IP receptor (prostacyclin pathway) | not yet graded | No reviewed efficacy summary in this indication | |
| HSK44459 | Phase 3 | Small molecule | PDE4B | not yet graded | No reviewed efficacy summary in this indication | |
| Treprostinil (Tyvaso) | Phase 3 | Small molecule | IP receptor (prostacyclin pathway) | not yet graded | No reviewed efficacy summary in this indication | |
| ABBV-722 | Phase 1(overall) | Small molecule | LPAR1 | not yet graded | No reviewed efficacy summary in this indication | |
| Iloprost (Ventavis) | Discontinued | Small molecule | IP receptor (prostacyclin pathway) | not yet graded | No reviewed efficacy summary in this indication | |
| Pamrevlumab | Discontinued | Monoclonal antibody | CTGF | not yet graded | No reviewed efficacy summary in this indication | |
| Voxelotor (Oxbryta) | Discontinued | Small molecule | Hemoglobin S (HbS) | not yet graded | No reviewed efficacy summary in this indication | |
| Ziritaxestat | Discontinued | Small molecule | autotaxin (ENPP2) | not yet graded | No reviewed efficacy summary in this indication |
Compare side by side
Upcoming events
(10 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Nerandomilast (Jascayd) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.